Clinical Trial: Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07064018) titled 'Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies' on May 27.

Brief Summary: This is a Phase 1b/IIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-tissue sarcoma (STS); triple-negative breast cancer (TNBC); Non-small cell lung cancer (NSCLC); cervical cancer; ovarian cancer; KRAS mutant pancreatic ductal adenocarcinoma. These are subjects who have not previously been treated with anthracyclines.

Study Start Date: April 30

Study Type: INTERVENTIONAL

Condition: Soft-tissue Sarcoma Triple Negative Breast Cancer...